Abstract. Scintigraphy with iodine-123 or indium-111 labelled somatostatin analogue (octreotide) was performed in 52 patients diagnosed as, suspected of, or at risk of having carcinoid tumours. In 32 of 37 (86%) patients in whom histologically proven carcinoids were still present, known tumour sites were visualized. Using 123I-coupled octreotide, 24 of 40 (60%) known extrahepatic sites were visualized, whereas all of 12 (100%) extrahepatic lesions were visualized after injection of rain-coupled octreotide. Known liver metastases were not distinctly visualized with octreotide scintigraphy in 12 of 24 patients. In all but two of these cases, an even distribution of radioactivity in the liver was observed. This is most probably due to the fact that these liver metastases accumulated about as much radioactivity as does normal liver tissue. Previously unsuspected localizations or sites not recognized with other imaging techniques were found in 20 of the 37 patients. In 3 of 11 patients who were thought to have been surgically cured, and in 4 of 4 patients who were suspected of having carcinoids, octreotide scintigraphy showed abnormal accumulation of radioactivity. Histological or radiological evidence that additional sites noticed on octreotide scintigrams indeed represented tumour tissue was obtained in ten patients. Visualization of the carcinoids did not depend on the site of the tumour or on the presence or absence of hormonal hypersecretion, as measured by urinary 5-hydroxyindoleacetic acid and serum c~-subunit concentrations. Apart from its use for tumour localization, octreotide scintigraphy, in consequence of its ability to demonstrate somatostatin receptor positive tumours, could be used to select those patients with the carcinoid syndrome who are likely to respond favourably to octreotide treatment.
Introduction
Carcinoid tumours, which stem from enterochromaffin cells, may arise throughout the body, but occur most often in the gastrointestinal tract and in the lung [1] . The carcinoid syndrome, characterized by flushing, diarrhoea, right-sided heart disease and wheezing is usually associated with carcinoids of the small bowel that are metastatic to the liver.
High numbers of high-affinity somatostatin binding sites have been found on carcinoid tumours [2] [3] [4] . Chronic treatment with the somatostatin analogue octreotide (Sandostatin) causes relief of symptoms and a decrease in urinary 5-hydroxyindoleacetic acid (5-HIAA) levels in most patients with the carcinoid syndrome [5] [6] [7] [8] .
We recently described the in vivo visualization of carcinoids after injection of a somatostatin analogue coupled to iodine-123 [9, 10] . Subsequently, an easier technique of in vivo visualization of somatostatin receptors using a somatostatin analogue coupled to indium-Ill was developed [11] [12] [13] . In this study, we report the results of scintigraphy with t 2 ai_ or 111in_labelled octreotide in 19 and 33 patients, respectively, who were suspected to have carcinoids. The results of octreotide scintigraphy are compared with the outcomes of other imaging techniques which were used in the diagnosis or follow-up of the patients.
Materials and methods
Patients. Fifty-two patients in whom 123i_ or 11 l labelled octreotide scintigraphy was performed, were studied. Inclusion required either histological confirmation of a carcinoid tumour of a present or previously operated lesion, or a history of carcinoid syndromerelated signs and symptoms. In all patients, data on previous symptomatology and treatment had to be present. Histologically proven carcinoids were present in 37 patients, 11 patients had undergone seemingly radical surgery and four patients were suspected to have carcinoids. The results of [123I-Tyr3]-octreotide scintigraphy in 13 patients of this series have been previously described in brief [10] . All patients gave informed consent to participation in the study, which was approved by the ethics committee of our hospital. [Tyr3]-octreotide was iodinated as described previously [14] . [DTPA-D-Phel]-octreotide was coupled to 111In as described elsewhere [11] .
The in vivo visualization of somatostatin receptor-positive tumours after injection of [123I-Tyr3]-octreotide has been described previously [9, 10, 15, 16] . Drawbacks of this in vivo receptor imaging technique are the scarce availability of chemically pure ~z3I and the high abdominal background of radioactivity, caused by principal clearance of this analogue via the liver [12] . Therefore, an 11 l in_labelled somatostatin analogue has been developed. This analogue is excreted mainly via the kidneys, 90% of the dose being present in the urine 24 h after injection. Because of its relatively long effective half-life, H~In-octreotide is a radionuclide-coupled somatostatin analogue which can be used to visualize somatostatin receptor-bearing tumours efficiently after 24 and 48 h, when interfering background radioactivity is minimized by renal clearance [12, 131. [123I-Tyr3]-octreotide (248-555 MBq) was injected in 19 patients, and [l*qn-DTPA-D-Phel]-octreotide (248-360 MBq) was injected in 33 patients. Planar images were obtained with a largefield-of-view gamma camera (Counterbalance 3700 and ROTA II, Siemens Gammasonics, Erlangen, Germany) equipped with a 190-keV parallel-hole collimator when [*23I-Tyr3]-octreotide was injected, and with a medium-energy collimator when [11 I ln_DTPA -D-Phel]-octreotide was injected. Static images were obtained 4 and 24 h after injection of the 123i_couple d somatostatin analogue, and 24 and 48 h after injection of the ~11In-coupled somatostatin analogue, because the background radioactivity at those times is low. Preset counts for images obtained 4 h after injection of the 123I-coupled somatostatin analogue or 24 h after injection of the 1**Incoupled somatostatin analogue were 300000 for the head and neck, and 500 000 for the remainder of the body; preset time was 15 rain for images obtained 24 h after injection of the 123I-coupled somatostatin analogue or 48 h after injection of the ~ ~ ~In-coupled somatostatin analogue [13] .
To define the tumours as visualized during this scanning procedure, we used a simple yes-or-no system. In each patient, the two subsequent scans (i.e. 4 and 24 h after injection of the ~23I-coupled somatostatin analogue, and 24 and 48 h after injection of the 1 * * Incoupled somatostatin analogue) were compared. As a rule, and especially in the abdomen, accumulation of radioactivity at an abnormal site was considered to represent somatostatin receptor binding only if it was present on the scintigrams of both standard imaging time points. We discarded images obtained up to 20 min after injection of 123I-coupled octreotide since it may be argued that hot spots observed at that time might be due to hypervascularization of the turnout. The scintigrams from all 52 patients were re-examined by two of us (EPK, HYO), without knowing the patient's identity, medical history, or outcomes of other investigations. If the interpretations differed, they were discussed until agreement was reached.
In order to compare the number of lesions demonstrated with conventional imaging techniques with those visualized during octreotide scintigraphy, the images were divided into parts easily recognizable on scintigrams, i.e. the head and neck, chest, upper abdomen, lower abdomen (division line: lower edges of the kidneys) and extremities.
The routine radiological examinations which were used in the diagnosis or follow-up of the patients (i.e. any combination of CT scan, ultrasonography, bone scan and chest X-ray) had been carried out in a number of hospitals. In most patients, however, CT scanning with a slice thickness of 12 mm had been performed.
In some patients, a technetium-99m microcolloid scan of the liver (185 MBq; Albu-Res, Solco, Birsfelden, Switzerland) was made after octreotide scintigraphy.
Urinary 5-HIAA was measured using a fluorimetric method. Serum c~-subunit concentrations were measured by radioimmunoassay using antibodies purchased from UCB (Brussels, Belgium). The sensitivity of the e-subunit assay was 0.3 gg/1 and the intraand interassay coefficients of variation were <6% and <11%, respectively [•7] . Table 1 . A t the time of scanning, two patients used serotonin antagonists, three were being treated with octreotide (100, 200 and 400 gg daily, respectively) and two were receiving interferon-e. Octreotide t h e r a p y was discontinued at least 1 day before the injection o f labelled octreotide and was resumed after the images had been made.
Results

Between
Histologically p r o v e n carcinoid t u m o u r s were present in 33 patients, whereas in four patients the r e m o v a l o f the t u m o u r or its metastases was k n o w n to be incomplete peroperatively (Tables •-3 
Patients with proven carcinoids
Counting liver metastases and also lymph node groups as one lesion, and more than five lesions in one part of the body as five lesions, 52 extrahepatic and 24 hepatic sites were visualized with conventional imaging techniques in the 37 patients who either had histologically proven tumours present or in whom not all tumour had been removed during surgery. Nineteen of 27 (70%) localizations in the head, neck and thorax, and 17 of 25 (68%) extrahepatic abdominal localizations were visualized. Twenty-four of 40 (60%) known extrahepatic lesions were visualized in patients in whom 123I-coupled 289 octreotide was injected, and 12 of 12 (J00%) known extrahepatic lesions were visualized in patients in whom 111In-coupled octreotide was injected (P<0.01, Fisher's exact test). The 16 known extrahepatic lesions that were not visualized after injection of 123I-coupled octreotide were present in four patients (patients 8, 15, 16 and 17, Table 2 ). Patients 15 and 16 had been treated with chemotherapy and radiotherapy, and chemotherapy and interferon, respectively, within the 12 months preceding octreotide scintigraphy. However, such treatment within a year before somatostatin receptor imaging had also been given in patients 1, 5, 25 and 34, in whom known lesions did accumulate labelled octreotide.
Accumulation of radioactivity at previously unsuspected localizations or sites not recognized with other imaging techniques was found in 4 of 17 patients (12 sites) in whom 123I-coupled octreotide was injected, and in 16 of 20 patients (36 sites) in whom llqn-coupled octreotide was injected.
Octreotide scintigraphy revealed presumed tumour spots in 22 of 24 patients with elevated urinary 5-HIAA, and in seven of eight patients with normal urinary 5-HIAA. In addition, octreotide imaging was positive in eight of ten patients with elevated serum c~-subunit, and in 15 of 16 patients with normal serum ~-snbunit (P > 0.05 for both markers; Fisher's exact test) (Tables 1-3 ).
In 12 of 24 patients who had liver metastases, no liver hot spots were detected using octreotide scintigraphy, whereas CT scanning and/or ultrasonography clearly demonstrated hypodensities (Tables 2, 3 ). The diameter of the liver metastases in these patients varied from 1 to 5 cm, whereas it ranged from I to 8 cm in those in whom liver hot spots were seen. In two of these patients (patients 16 and 39), cold spots were seen during octreotide scintigraphy. A comparison between octreotide scintigraphy and 99mTc-colloid scintigraphy of the liver in patient 13 (Fig. 4) reveals that the liver metastases, visible as cold spots on the colloid scintigram, accumulated ~23I-labelled octreotide, although to a lesser degree than the physiological accumulation in normal liver tissue. Surgically "cured" patients In 3 out of 11 patients who were thought to be surgically cured, octreotide scintigraphy showed abnormal accumulation of radioactivity. In patient 40, subsequent CT scanning of the abdomen demonstrated a retroperitoneal lymph node with a diameter of 1 cm in the upper abdomen; contrast-enhanced thin-slice CT scanning of the thorax, however, revealed no abnormalities which could explain the clearly visible accumulation of radioactivity in the lower left lung during octreotide scintigraphy. In patient 41, a CT scan performed 5 months after octreotide scintigraphy, because of the abdominal hot spot seen during the latter investigation, showed a hypodensity with a diameter of 1.5 cm near or in the ascending colon. In patient 42, no follow-up imaging was available.
Patients suspected of having carcinoids
In all four patients who were suspected to have carcinoids, an abnormal accumulation of radioactivity in the abdomen was observed during octreotide scintigraphy. In patient 49, CT scanning demonstrated a lesion with a diameter of 2 cm ventromedial to the right kidney. Repeated octreotide scintigraphy, 5 and 12 months after the initial imaging, demonstrated a persisting abnormal accumulation of radioactivity at the same site. In patient 50 the spot of radioactive accumulation during ~aIn-octreotide scintigraphy coincided with a duodenal diverticulum according to CT scanning. In patient 51, CT scanning subsequent to octretoide scintigraphy revealed a hypodensity in the caecum; during colonoscopy, however, no abnormality was observed. In patient 52, no abnormalities were seen during CT scanning.
Confirmation of additional tumour localizations
In four patients in whom octreotide scintigraphy demonstrated more presumed abdominal tumour localizations than did conventional imaging techniques, histological confirmation for these additional sites was obtained afterwards. In patient 37, liver metastases, but also small tumour deposits in the ileum, were found during surgery. Autopsy performed 7 and 8 months after octreotide scintigraphy, respectively, revealed multiple tumour deposits in the abdomen in patient 2 and a tumour in the ileum in patient 4. In patient 23, histologically proven carcinoids of the stomach could be visualized with octreotide scintigraphy, but not with CT scan and ultrasonography. In two other patients (patients 27 and 32), localizations that were seen on octreotide scintigrams and were not detected with other imaging techniques performed at that time were much later confirmed by conventional imaging techniques. In patient 27, a chest X-ray performed 2 years after octreotide scintigraphy demonstrated a lesion in the left lung top, a site where octreotide scintigraphy had previously suggested tumour deposit. In patient 32, ultrasonography, performed 1 year after octreotide scintigraphy, demonstrated swollen walls in the sigmoid, whereas during somatostatin receptor imaging abnormal accumulation of radioactivity in the lower abdomen had been noticed.
Discussion
In contrast to bronchial carcinoids, small bowel carcinoids are often hard to localize by CT scanning [7] . Imaging of carcinoid tumours using 131I-metaiodobenzylguanidine has a sensitivity of 40%-60% [18] [19] [20] . By contrast, ~23I-or ltlin_octreotide scintigraphy demonstrated presumed tumour sites in 32 of 37 patients (86%) with histologically proven carcinoid tumours present, whether localized in the lung or in the gastrointestinal tract. In five patients, no uptake of radiolabelled octreotide was observed at any of the tumour sites. In three of these patients, the tumours were localized in the chest. However, in six other patients carcinoid localizations in the lung did accumulate radioactivity. Apparently, the localization of the tumour is not a determining factor in the visualization of carcinoids with labelled octreotide.
Elevated serum e-subunit levels have been reported in patients with carcinoids [21, 22] . Also, in rectal carcinoids it has been shown that immunoreactivity for serotonin and e-subunit is present in the same cell [23] . In our series, the absence or presence of serotonin or ~-subunit production by the tumour, as reflected in elevated urinary 5-HIAA or serum e-subunit concentrations, was not related to the outcome of octreotide scintigraphy, as carcinoids could be visualized both in patients with and in patients without elevated urinary 5-HIAA or serum ct-subunit levels.
A significantly higher percentage of extrahepatic sites were visualized in patients in whom 11 lin_octreotid e was injected, as compared to those in whom ~23I-octreotide was injected. However, 13 of 16 extrahepatic lesions that were not visualized during 123I-octreotide scintigraphy were present in two patients who had had recent radiotherapy and chemotherapy. Though carcinoid localizations were visualized in other patients who had also recently been treated in this way, it cannot be excluded that recent chemotherapy and radiotherapy influenced the somatostatin receptor status of the tumours in these two patients. In three patients who were treated with octreotide, this treatment was discontinued at least 1 day before injection of labelled octreotide. In all three patients, the carcinoids clearly accumulated radioactivity. This could mean either that discontinuation of octreotide therapy for ! day is sufficient to make somatostatin receptors available for binding of labelled octreotide, or, alternatively, that not all somatostatin receptors are occupied during octreotide treatment.
In 12 of 24 patients who had liver metastases, the metastases were not detected using octreotide scintigraphy, whereas CT scanning and/or ultrasonography clearly demonstrated hypodensities. Metastases visualized as cold spots in the normal distribution of radioactivity in the liver were present in only two patients. These metastases can therefore be regarded as truly somatostatin receptor negative. In the other ten patients, however, an even distribution of radioactivity in the liver was observed. As the diameter of the liver metastases in these patients did not differ from that observed in patients whose liver metastases were visualized, and as, moreover, other tumour sites in the same patients clearly accumulated labelled octreotide, it must be assumed that these liver metastases accumulated about as much radioactivity as does normal liver tissue. Single photon emission tomography studies might be useful in this respect, as an irregular distribution of radioactivity was observed in three of four patients in whom planar images showed an even uptake of liver radioactivity (data not shown).
Apart from the visualization of known lesions, previously unsuspected localizations or sites not recognized with other imaging techniques were found in 20 of 37 patients with proven carcinoids. Although the conventional imaging regime used was not the same in each patient, CT scanning with a slice distance of 12 mm of parts of the body in which octreotide scintigraphy suggested tumour deposits had been performed in 15 of 20 patients. In most patients the additional sites which were seen on octreotide scintigrams were localized in the abdomen. The finding of more abdominal tumour sites using octreotide scintigraphy is of special interest as the primary localization of intestinal carcinoids is often not detected with other imaging techniques [7] . In this respect, results obtained with the 11~In-labelled somatostatin analogue, demonstrating unsuspected abdominal spots in 12 of 20 patients, seeemed superior to those obtained with ~23I-labelled octreotide, which showed unsuspected abdominal sites in only 4 of 17 patients. Also, in two patients, extrahepatic abdominal tumour sites demonstrated with CT scanning or ultrasonography could not be visualized with 123I-octreotide scintigraphy. This is probably because ~23I-octreotide is excreted into the bile, which causes a high background of radioactivity in the abdomen [14] . By contrast, t ~ lInoctreotide is excreted mainly via the kidneys, leaving the upper abdomen with less background radioactivity [12, 13] .
The specificity of octreotide scintigraphy for carcinoids may be questioned, especially in those cases in which tumour deposits were suggested with octreotide scintigraphy, but could not be demonstrated with CT scanning. In one patient, the spot of radioactive accumulation during ~qn-octreotide scintigraphy coincided with a duodenal diverticulum on CT scanning, but it is not known whether carcinoid tissue was present in the diverticulum. However, in ten patients in whom octreotide scintigraphy suggested more tumour deposits than CT scanning, histological or radiological evidence was obtained that the sites of accumulation of radioactivity indeed represented tumour tissue.
Unfortunately, our series included only two patients with a carcinoid of the appendix. Recurrence of these tumours after appendectomy has been reported to depend on the size of the turnout. In a long-term study of 150 patients with carcinoid tumours of the appendix, Moertel et al. [24] found no metastases from tumours < 2.0 cm in largest dimension, whereas metastases were observed from 3 of 14 lesions >2 cm and 4 of 9 lesions _> 3 cm. The authors conclude that right hemicolectomy seems justified in young patients with turnouts > 2 cm who have a low risk of operative morbidity or mortality. Octreotide scintigraphy in these patients might provide useful additional information.
Apart from its use for tumour localization, octreotide scintigraphy can also be used to differentiate those patients who have somatostatin receptor positive turnouts from those who have somatostatin receptor negative ones. Treatment with octreotide may cause relief of symptoms and a decrease in urinary 5-HIAA levels in patients with the carcinoid syndrome [5] [6] [7] [8] . In patients with the carcinoid syndrome, octreotide scintigraphy, in consequence of its ability to demonstrate somatostatin receptor positive tumours, could be used to select those patients who are likely to respond favourably to octreotide treatment.
In conclusion:
1. In the majority of patients with carcinoid turnouts, these tumours could be visualized using octreotide scintigraphy. 2. Visualization of carcinoid tumours during octreotide scintigraphy did not depend on tumour site or presence or absence of hormonal hypersecretion. 3. Known liver metastases were not distinctly visualized with octreotide scintigraphy in half of the patients. This is most probably due to the fact that the liver metastases in these patients accumulated about as much radioactivity as does normal liver tissue. 4. a 1 lin_octreotid e scintigraphy seemed superior to 123I-octreotide scintigraphy in detecting extrahepatic carcinoid lesions. 5. Using octreotide scintigraphy, previously unsuspected localizations or sites not recognized with other imaging techniques were found in the majority of patients. In 10 of 27 patients, histological or radiological evidence was obtained that these additional sites indeed represented tumour tissue. 6. Apart from its use for tumour localization, octreotide scintigraphy, in consequence of its ability to demonstrate somatostatin receptor positive tumours, could be used to select those patients with the carcinoid syndrome who are likely to respond favourably to octreotide treatment.
